Genentech Seeks Trim Of Eli Lilly's Patent Invalidation Suit

Law360, Los Angeles (October 30, 2013, 10:12 PM EDT) -- Genentech Inc. on Wednesday urged a California federal judge to trim a suit seeking to invalidate its patents for a blood cancer treatment, saying Eli Lilly and Co. had failed to show a Genentech attorney and others engaged in inequitable conduct in prosecuting the patents.

While there is controversy in the federal courts over what exactly constitutes inequitable conduct, Genentech's attorney Daralyn Durie said, Eli Lilly had not pleaded sufficient facts in its complaint to show the patents were unenforceable because any of a number of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.